Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple-antibiotic therapy for coronary heart disease
ACTRN12618000260224Phase 2Recruiting
- Sponsor
- Centre for Digestive Diseases
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doxycycline, azithromycin and rifabutin in coronary arteriosclerosis and Chlamydia pneumoniae infection, sponsored by Centre for Digestive Diseases. Primary endpoint: Improvement in coronary flow by fractional flow reserve. Started Apr 2018; status: recruiting.
02
Drugs
doxycyclineazithromycinrifabutin
03
Conditions
coronary arteriosclerosisChlamydia pneumoniae infection
Beyond the preview
Go deeper on ACTRN12618000260224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000260224.